Ann Dermatol.  2009 Nov;21(4):419-422. 10.5021/ad.2009.21.4.419.

A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision

• Choi JW
• Choi M
• Cho KH

• KMID: 2156511
• DOI: http://doi.org/10.5021/ad.2009.21.4.419

Abstract

Imiquimod is a new immunomodulating agent with antitumor and antiviral properties that has been shown to be clinically effective in various kinds of skin diseases, including precancerous dermatoses. Erythroplasia of Queyrat is a carcinoma in situ that mainly occurs on the glans penis. There are several non-invasive treatment options for erythroplasia of Queyrat such as photodynamic therapy, cryosurgery and applying various kinds of topical agents. We now report a case of typical erythroplasia of Queyrat on glans penis associated with human papillomavirus type 16 infection that was treated by imiquimod 5% cream and the subsequent excision of an imiquimod-resistant penile lesion.

Keyword

Erythroplasia of Queyrat; Imiquimod

MeSH Terms

Aminoquinolines
Carcinoma in Situ
Cryosurgery
Erythroplasia
Humans
Male
Penis
Photochemotherapy
Skin Diseases
Aminoquinolines

Figure

• 

  Fig. 1 (A) EQ of the glans, appearing as a shiny, erythematous and slightly infiltrated plaque involving the urinary meatus. (B) Clinical improvement after 24 weeks of imiquimod treatment.

• 

  Fig. 2 Biopsy shows acanthosis with dyskeratotic cells. Keratinocytes at all levels of the epidermis show a partial loss of polarity, increased mitoses, and cellular atypia (H&E stain, ×200).

• 

  Fig. 3 A HPV DNA chip test was done to identify the type of HPV. Arrows indicate that the HPV detected in the biopsy specimen is type 16.

Reference

1. Graham JH, Helwig EB. Erythroplasia of Queyrat. A clinicopathologic and histochemical study. Cancer. 1973. 32:1396–1414.

2. Mikhail GR. Cancers, precancers, and pseudocancers on the male genitalia. A review of clinical appearances, histopathology, and management. J Dermatol Surg Oncol. 1980. 6:1027–1035.

3. Peterka ES, Lynch FW, Goltz RW. An association between Bowen's disease and internal cancer. Arch Dermatol. 1961. 84:623–629.

4. Kao GF. Carcinoma arising in Bowen's disease. Arch Dermatol. 1986. 122:1124–1126.

5. Wieland U, Jurk S, Weissenborn S, Krieg T, Pfister H, Ritzkowsky A. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol. 2000. 115:396–401.

6. Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E. Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev. 2001. 25:533–547.

7. Stables GI, Stringer MR, Robinson DJ, Ash DV. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1999. 140:514–517.

8. Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs. 1999. 58:375–390.

9. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002. 3:196–200.

10. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999. 21:1–14.

11. Arlette JP. Treatment of Bowen's disease and erythroplasia of Queyrat. Br J Dermatol. 2003. 149:Suppl 66. 43–49.

12. Micali G, Nasca MR, De Pasquale R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol. 2006. 55:901–903.

13. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med. 2002. 47:701–705.